Investors in Regeneron Pharmaceuticals Facing Deadline for Class Action Lawsuit Over Trial Failures

In a significant legal development for shareholders, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently under scrutiny as a class action lawsuit has emerged in the wake of a disappointing Phase 3 clinical trial for its melanoma therapy. This comes after a notable downturn in the company's stock following the revelation of the trial's failure, which led to an $11 billion drop in market capitalization.

The renowned law firm Hagens Berman Sobol Shapiro LLP is spearheading the legal action, focusing on investors who purchased shares between August 1, 2025, and May 15, 2026. The firm has alerted affected investors that the lead plaintiff deadline is approaching, set for September 14, 2026.

Background of the Case

The clinical trial in question aimed to assess Fianlimab in combination with Libtayo as a potential first-line treatment for advanced melanoma. Regeneron touted the treatment as a possible breakthrough, referring to it as a "potential blockbuster". However, the trial's primary endpoint, which was progression-free survival (PFS), failed to show statistical significance as initially promised.

Throughout the class period, firm assurances were given to investors regarding the positive outcomes of the trial. Despite consistent optimism from management, internal flaws in trial assumptions and data interpretation were not disclosed, leading to accusations of misleading statements. Investors are now questioning whether they were kept in the dark about the mounting evidence suggesting the trial might not achieve its primary goal.

Timeline of Events

The turning point came on April 29, 2026, when Regeneron announced alterations to the trial protocol, which raised eyebrows among analysts who speculated that these modifications were indicative of underlying issues that were not adequately acknowledged by management. Just weeks later, on May 12, Regeneron confessed that these changes were a response to "slow event rates," effectively undermining their earlier claims of unwavering confidence in trial outcomes.

The grim reality became evident on May 15, 2026, when Regeneron officially stated that the trial did not achieve the necessary statistical significance regarding improvement in PFS.

Implications for Investors

This class action lawsuit is poised to hold Regeneron accountable for its handling of the trial and communication with the market. Hagens Berman emphasizes the importance of collection evidence from affected investors and is actively seeking those who may have experienced significant financial losses due to Regeneron's actions. Investors who suffered losses during the class period are encouraged to come forward and participate in the ongoing legal proceedings.

Moreover, whistleblowers with non-public information about the Trials are urged to assist in the investigation. Under the SEC Whistleblower program, there are potential rewards for original information leading to a recovery by the SEC.

Hagens Berman's Commitment

Hagens Berman is known for its commitment to holding corporations accountable and representing victims of corporate misconduct. The return from this lawsuit could be substantial, as the firm has previously recovered over $2.9 billion for its clients.

As the September deadline approaches, it’s recommended that any investor connected to Regeneron take action to protect their rights and potential recovery. More information regarding the case and how to join the lawsuit can be found by contacting Hagens Berman or visiting their dedicated site for Regeneron investors.

In conclusion, the ongoing scrutiny of Regeneron Pharmaceuticals not only emphasizes the importance of transparency in clinical trials but also highlights the necessity for shareholders to remain vigilant and informed regarding the companies in which they invest.